Search filters

List of works by Ranjana H. Advani

2 Gy × 2 for palliative treatment of mantle cell lymphoma

scientific article published on 14 January 2016

A 3-Arm Randomized Phase II Study of Bendamustine/Rituximab with Bortezomib Induction or Lenalidomide Continuation in Untreated Follicular Lymphoma: ECOG-ACRIN E2408

scientific article published on 12 June 2020

A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T-cell lymphoma

scientific article

A Phase II trial of aprinocarsen, an antisense oligonucleotide inhibitor of protein kinase C alpha, administered as a 21-day infusion to patients with advanced ovarian carcinoma

scientific article

A multicenter phase II trial to determine the safety and efficacy of combination therapy with denileukin diftitox and cyclophosphamide, doxorubicin, vincristine and prednisone in untreated peripheral T-cell lymphoma: the CONCEPT study.

scientific article

A multicentre study of primary breast diffuse large B-cell lymphoma in the rituximab era.

scientific article published on 27 January 2014

A phase I trial of aprinocarsen (ISIS 3521/LY900003), an antisense inhibitor of protein kinase C-alpha administered as a 24-hour weekly infusion schedule in patients with advanced cancer

scientific article

A phase I weekly dosing study of brentuximab vedotin in patients with relapsed/refractory CD30-positive hematologic malignancies

scientific article published on 11 November 2011

A phase II study of cyclophosphamide, etoposide, vincristine and prednisone (CEOP) Alternating with Pralatrexate (P) as front line therapy for patients with peripheral T-cell lymphoma (PTCL): final results from the T- cell consortium trial

scientific article

A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

scientific article

A phase II trial of RCHOP followed by radioimmunotherapy for early stage (stages I/II) diffuse large B-cell non-Hodgkin lymphoma: ECOG3402

scientific article

A prognostic index for natural killer cell lymphoma after non-anthracycline-based treatment: a multicentre, retrospective analysis

scientific article

A prospective cohort study of patients with peripheral T-cell lymphoma in the United States

scientific article

A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy

scientific article published on 10 July 2015

ABCL-455 Multicenter Retrospective Analysis of Single-Route Prophylaxis in Aggressive B-Cell Lymphomas

ACR Appropriateness Criteria Pediatric Hodgkin Lymphoma

scientific article published on 24 February 2014

ACR Appropriateness Criteria® Diffuse Large B-Cell Lymphoma

scientific article published on December 2015

ACR Appropriateness Criteria® Hodgkin Lymphoma-Favorable Prognosis Stage I and II.

scientific article published on 16 September 2016

ACR Appropriateness Criteria® Hodgkin Lymphoma-Unfavorable Clinical Stage I and II.

scientific article published on 13 June 2016

ACR Appropriateness Criteria® on Hodgkin's lymphoma-unfavorable clinical stage I and II.

scientific article published on May 2011

ACR appropriateness criteria follow-up of Hodgkin lymphoma.

scientific article published on 30 September 2014

Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia.

scientific article published on 24 February 2017

Activating Immune Effectors and Dampening Immune Suppressors Generates Successful Therapeutic Cancer Vaccination in Patients with Lymphoma

Advances in the management of primary mediastinal large B-cell lymphoma

scientific article published in January 2018

Age, Albumin, and LDH Predict Outcome of Patients with Limited Stage Peripheral T Cell Lymphoma: A Prognostic Model Developed on 244 Cases Enrolled in the T Cell Project 1 By the International T Cell Project Network

Allogeneic transplant following brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic large cell lymphoma.

scientific article

Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation

scientific article published on 01 July 2018

Analysis of Peripheral T-cell Lymphoma Diagnostic Workup in the United States

scientific article published on 10 January 2017

Angioimmunoblastic T cell lymphoma: treatment experience with cyclosporine

scientific article published on 01 March 2007

Anti-CD30 antibody–drug conjugate therapy in lymphoma: current knowledge, remaining controversies, and future perspectives

Anti-CD79B Antibody–Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study

Anxiety and health-related quality of life among patients with low-tumor burden non-Hodgkin lymphoma randomly assigned to two different rituximab dosing regimens: results from ECOG trial E4402 (RESORT).

scientific article

Autologous EBV-specific T cell treatment results in sustained responses in patients with advanced extranodal NK/T lymphoma: results of a multicenter study

Autologous tumor cell vaccine induces antitumor T cell immune responses in patients with mantle cell lymphoma: A phase I/II trial

scientific article published on 01 September 2020

Bevacizumab and cyclosphosphamide, doxorubicin, vincristine and prednisone in combination for patients with peripheral T-cell or natural killer cell neoplasms: an Eastern Cooperative Oncology Group study (E2404).

scientific article

Beyond the guidelines in the treatment of peripheral T-cell lymphoma: new drug development

scientific article published in April 2008

Breast Imaging in Women Previously Irradiated for Hodgkin Lymphoma

scientific article

Brentuximab Vedotin Combined with Chemotherapy in Newly Diagnosed, Early-Stage, Unfavorable-Risk Hodgkin Lymphoma: Extended Follow-up with Evaluation of Baseline Metabolic Tumor Volume and PET2

Brentuximab Vedotin plus Chemotherapy in North American Subjects with Newly Diagnosed Stage III or IV Hodgkin Lymphoma

scientific article published on 07 January 2019

Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study

scientific article

Brentuximab vedotin activity in diffuse large B-cell lymphoma with CD30 undetectable by visual assessment of conventional immunohistochemistry

scientific article

Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression.

scientific article published on 8 January 2015

Brentuximab vedotin does not cause clinically relevant QTc interval prolongation in patients with CD30-positive hematologic malignancies ⬇️

scientific article published on May 30, 2013

Brentuximab vedotin in the front-line treatment of patients with CD30+ peripheral T-cell lymphomas: results of a phase I study

scientific article

Brentuximab vedotin in transplant-naive patients with relapsed or refractory hodgkin lymphoma: analysis of two phase I studies

scientific article

Brentuximab vedotin plus bendamustine: a highly active first salvage regimen for relapsed or refractory Hodgkin lymphoma

scientific article published on 27 April 2018

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

scientific article published on 04 December 2018

Brentuximab vedotin with chemotherapy for stage III or IV classical Hodgkin lymphoma (ECHELON-1): 5-year update of an international, open-label, randomised, phase 3 trial

Brentuximab vedotin with chemotherapy for stage III/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study

scientific article published on 01 March 2020

Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies

scientific article

Bruton tyrosine kinase inhibitors: a promising novel targeted treatment for B cell lymphomas

scientific article

Bruton's tyrosine kinase inhibitors in chronic lymphocytic leukemia and lymphoma

scientific article

Bulky mediastinal classical Hodgkin lymphoma in young women

scientific article published on March 2014

CD20-Negative Nodular Lymphocyte-Predominant Hodgkin Lymphoma: A 20-Year Consecutive Case Series From a Tertiary Cancer Center

scientific article published on 29 September 2020

CD20-Targeted Therapy Ablates De Novo Antibody Response to Vaccination but Spares Pre-Established Immunity

scientific article

CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma

scientific article published on March 2011

CD47 Blockade and Rituximab in Non-Hodgkin's Lymphoma

scientific article published on 01 January 2019

CD47 Blockade by Hu5F9-G4 and Rituximab in Non-Hodgkin's Lymphoma

scientific article published on 01 November 2018

Cancer vaccines and T cell therapy

scientific article

Cardiac toxicity associated with bevacizumab (Avastin) in combination with CHOP chemotherapy for peripheral T cell lymphoma in ECOG 2404 trial

scientific article published on 05 December 2011

Characteristics and Outcome of Extranodal NK/T-Cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

Characteristics and Outcome of Extranodal NK/T-cell Lymphoma in North America: A Retrospective Multi-Institutional Experience

Checkpoint Blockade Treatment May Sensitize Hodgkin Lymphoma to Subsequent Therapy

scientific article published on 28 July 2020

Checkpoint blockade treatment sensitises relapsed/refractory non-Hodgkin lymphoma to subsequent therapy

scientific article published on 19 May 2020

Checkpoint inhibitor‐based salvage regimens prior to autologous stem cell transplant improve event‐free survival in relapsed/refractory classic Hodgkin lymphoma

Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015

scientific article published on March 2015

Circulating Tumor DNA Measurements As Early Outcome Predictors in Diffuse Large B-Cell Lymphoma

scientific article published on 20 August 2018

Classical Hodgkin Lymphoma with Reduced β2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status

scientific article published on 13 October 2016

Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

scientific article

Clinical Practice Recommendations on Indication and Timing of Hematopoietic Cell Transplantation in Mature T Cell and NK/T Cell Lymphomas: An International Collaborative Effort on Behalf of the Guidelines Committee of the American Society for Blood a

scientific article published on 07 August 2017

Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia

scientific article

Comparison of conventional prognostic indices in patients older than 60 years with diffuse large B-cell lymphoma treated with R-CHOP in the US Intergroup Study (ECOG 4494, CALGB 9793): consideration of age greater than 70 years in an elderly prognos

scientific article published on October 2010

Consensus Statement on the Management of Waldenström Macroglobulinemia Patients During the COVID-19 Pandemic

scientific article published on 30 July 2020

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

scientific article published on 01 November 2020

Correction: First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL

scientific article published on 04 June 2019

Current concepts and controversies in the management of early stage Hodgkin lymphoma

scientific article

Customized targeted therapy in Hodgkin lymphoma: hype or hope?

scientific article

Cutaneous involvement by angioimmunoblastic T-cell lymphoma: a unique histologic presentation, mimicking an infectious etiology

scientific article published on September 2006

DLBCL-Morph: Morphological features computed using deep learning for an annotated digital DLBCL image set

scientific article

Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind,

scientific article published on 26 February 2015

Diffuse Large B-Cell Lymphoma Version 1.2016

scientific article published on 01 February 2016

Diffuse Large B-Cell Lymphoma: Prospective Multicenter Comparison of Early Interim FLT PET/CT versus FDG PET/CT with IHP, EORTC, Deauville, and PERCIST Criteria for Early Therapeutic Monitoring

scientific article published on 08 February 2016

Distinct Molecular Subtypes of Classic Hodgkin Lymphoma Identified By Comprehensive Noninvasive Profiling

Distinct biological subtypes and patterns of genome evolution in lymphoma revealed by circulating tumor DNA.

scientific article

Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma

scientific article

Dramatic Response with Single-Agent Ibrutinib in Multiply Relapsed Marginal Zone Lymphoma with MYD88L265P Mutation

scientific article published on 12 September 2017

Dynamic CD8 T-cell responses to tumor-associated Epstein-Barr virus antigens in patients with Epstein-Barr virus-negative Hodgkin's disease

scientific article published on January 2009

Efficacy of abbreviated Stanford V chemotherapy and involved-field radiotherapy in early-stage Hodgkin lymphoma: mature results of the G4 trial ⬇️

scientific article published on November 7, 2012

End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making

scientific article published on 10 May 2018

Epstein-Barr virus-associated lymphoproliferative disorder following autologous bone marrow transplantation for non-Hodgkin's lymphoma

scientific article published in June 1993

Erratum to: Clinical Impact of the 2016 Update to the WHO Lymphoma Classification

scientific article published in October 2017

Evaluation and management of angioimmunoblastic T-cell lymphoma: a review of current approaches and future strategies.

scientific article published on December 2008

Evaluation of the International Prognostic Score (IPS-7) and a Simpler Prognostic Score (IPS-3) for advanced Hodgkin lymphoma in the modern era

scientific article published on 07 September 2015

Exploratory Analysis of Factors Influencing Efficacy and Safety of Camidanlumab Tesirine: Data from the Open-Label, Multicenter, Phase 2 Study of Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

Extranodal natural killer/T-cell lymphoma: current concepts in biology and treatment

scientific article

F-Fluorothymidine PET is an early and superior predictor of progression-free survival following chemoimmunotherapy of diffuse large B cell lymphoma: a multicenter study

Final Results from a Phase 2 Study of Tipifarnib in Subjects with Relapsed or Refractory Peripheral T-Cell Lymphoma

First-in-human phase 1 study of the BTK inhibitor GDC-0853 in relapsed or refractory B-cell NHL and CLL.

scientific article published on 22 January 2018

Five-Year Outcomes for Frontline Brentuximab Vedotin with CHP for CD30 Expressing Peripheral T-Cell Lymphomas

scientific article published on 5 March 2018

Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma

scientific article published on 3 October 2017

Frontline Treatment with Single Agent Pembrolizumab (PEM) Followed By AVD Chemotherapy for Classic Hodgkin Lymphoma: Updated Results and Correlative Analysis

Gene expression-based model using formalin-fixed paraffin-embedded biopsies predicts overall survival in advanced-stage classical Hodgkin lymphoma

scientific article published on 26 November 2012

Genomic and microenvironmental landscape of stage I follicular lymphoma, compared with stage III/IV

Genomic profiling for clinical decision making in lymphoid neoplasms

Granulocyte-macrophage colony-stimulating factor (GM-CSF) as an adjunct to autologous hemopoietic stem cell transplantation for lymphoma

scientific article published in February 1992

Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohort.

scientific article published on 4 June 2015

HL-339 Camidanlumab Tesirine: Updated Efficacy and Safety in an Open-Label, Multicenter, Phase 2 Study of Patients With Relapsed or Refractory Classical Hodgkin Lymphoma (R/R cHL)

HL-507 First-Line Brentuximab Vedotin Plus Chemotherapy Improves Overall Survival in Patients With Stage III/IV Classical Hodgkin Lymphoma: An Updated Analysis of ECHELON-1

Hodgkin Lymphoma Version 1.2017, NCCN Clinical Practice Guidelines in Oncology

scientific article published on 01 May 2017

Hodgkin Lymphoma, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

scientific article published on 01 June 2020

Hodgkin Lymphoma: the Changing Role of Radiation Therapy in Early-Stage Disease—the Role of Functional Imaging

scientific article published on September 2015

Hodgkin lymphoma

scientific article published on 01 September 2011

Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines

scientific article published in May 2012

Hodgkin lymphoma, version 2.2015.

scientific article

How I treat nodular lymphocyte predominant Hodgkin lymphoma

scientific article

How to Provide Gadolinium-Free PET/MR Cancer Staging of Children and Young Adults in Less than 1 h: the Stanford Approach

scientific article published on 18 July 2017

Ibrutinib in Waldenström macroglobulinemia: latest evidence and clinical experience

scientific article

Ibrutinib in previously treated Waldenström's macroglobulinemia.

scientific article

Ibrutinib-associated rash: a single-centre experience of clinicopathological features and management.

scientific article

Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin Lymphoma

scientific article published on 10 April 2020

Impact of ibrutinib dose intensity on patient outcomes in previously treated Waldenström macroglobulinemia

scholarly article by Jorge J Castillo et al published October 2018 in Haematologica

Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin's disease

scientific article published on 30 July 2007

Improved outcomes after autologous bone marrow transplantation for children with relapsed or refractory Hodgkin lymphoma: twenty years experience at a single institution.

scientific article

Improved outcomes for relapsed/refractory Hodgkin lymphoma after autologous transplantation in the era of novel agents

Improvements in observed and relative survival in follicular grade 1-2 lymphoma during 4 decades: the Stanford University experience

scientific article published on 18 June 2013

Improving Care With a Portfolio of Physician-Led Cancer Quality Measures at an Academic Center

scientific article published on 20 July 2017

In situ vaccination against mycosis fungoides by intratumoral injection of a TLR9 agonist combined with radiation: a phase 1/2 study

scientific article published on November 2011

In situ vaccination with a TLR9 agonist induces systemic lymphoma regression: a phase I/II study

scientific article

Incidence and outcomes of rare T cell lymphomas from the T Cell Project: hepatosplenic, enteropathy associated and peripheral gamma delta T cell lymphomas

scientific article published on 25 November 2019

Increased double-negative αβ+ T-cells reveal adult-onset autoimmune lymphoproliferative syndrome in a patient with IgG4-related disease

Indolent primary cutaneous B-cell lymphoma: experience using systemic rituximab

scientific article published on 24 September 2008

Interim positron emission tomography scans in diffuse large B-cell lymphoma: an independent expert nuclear medicine evaluation of the Eastern Cooperative Oncology Group E3404 study

scientific article

Interim results of brentuximab vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma

scientific article published on 11 December 2017

Interim-treatment quantitative PET parameters predict progression and death among patients with Hodgkin's disease.

scientific article

International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017).

scientific article published on 3 April 2017

Investigating and modeling positron emission tomography factors associated with large cell transformation from low‐grade lymphomas

Ipilimumab, nivolumab, and brentuximab vedotin combination therapies in patients with relapsed or refractory Hodgkin lymphoma: phase 1 results of an open-label, multicentre, phase 1/2 trial

scientific article published on 01 September 2020

KLHL6 Is Preferentially Expressed in Germinal Center-Derived B-Cell Lymphomas.

scientific article published on 11 November 2017

Lack of reproducibility of histopathological features in MYC ‐rearranged large B cell lymphoma using digital whole slide images: a study from the Lunenburg lymphoma biomarker consortium

Long-Term Follow-Up of Ibrutinib Monotherapy in Symptomatic, Previously Treated Patients With Waldenström Macroglobulinemia

scientific article published on 15 September 2020

Long-Term Outcomes of Patients with Early-Stage Non-Bulky Hodgkin Lymphoma Treated with Combined Modality Therapy on the Stanford V Trials (The G4 and G5 Studies)

scientific article published on 29 December 2020

Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results

scientific article

Long-term outcomes of patients with unfavorable stage I-II classic Hodgkin lymphoma treated with Stanford V chemotherapy and limited field irradiation

scientific article published on 30 May 2020

Lymphoma cell VEGFR2 expression detected by immunohistochemistry predicts poor overall survival in diffuse large B cell lymphoma treated with immunochemotherapy (R-CHOP).

scientific article

Lymphoma in pregnancy initially diagnosed as vaginal intraepithelial neoplasia and lichen planus.

scientific article published in August 2011

Lymphoma occurring during pregnancy: antenatal therapy, complications, and maternal survival in a multicenter analysis.

scientific article

Magnetic Resonance Imaging of Tumor-Associated Macrophages: Clinical Translation

scientific article published on 15 May 2018

Magrolimab in Combination with Rituximab + Chemotherapy in Patients with Relapsed or Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Management of B-cell non-Hodgkin lymphoma in Asia: resource-stratified guidelines

scientific article

Management of T-cell and natural-killer-cell neoplasms in Asia: consensus statement from the Asian Oncology Summit 2009.

scientific article

Management of advanced stage Hodgkin lymphoma

scientific article

Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.

scientific article published in May 2015

Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 10 February 2014

MicroRNAs are independent predictors of outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

scientific article

Mitoxantrone, etoposide, and cytarabine with or without valspodar in patients with relapsed or refractory acute myeloid leukemia and high-risk myelodysplastic syndrome: a phase III trial (E2995)

scientific article

Modern principles in the management of nodular lymphocyte-predominant Hodgkin lymphoma

scientific article published on 28 November 2018

Multicenter Phase II Study of Sequential Brentuximab Vedotin and Doxorubicin, Vinblastine, and Dacarbazine Chemotherapy for Older Patients With Untreated Classical Hodgkin Lymphoma

article

Multicenter clinical trial of bortezomib in relapsed/refractory Waldenstrom's macroglobulinemia: results of WMCTG Trial 03-248.

scientific article

Multicenter phase 1 trial of intraventricular immunochemotherapy in recurrent CNS lymphoma

scientific article published on 29 November 2012

NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas

scientific article

NCCN Guidelines Insights: B-Cell Lymphomas, Version 3.2019

scientific article published on 01 June 2019

NCCN Guidelines Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia, Version 1.2017.

scientific article

NCCN Guidelines Insights: Hodgkin Lymphoma, Version 1.2018

scientific article published on 01 March 2018

NCCN Guidelines Insights: Non-Hodgkin's Lymphomas, Version 3.2016.

scientific article

NCCN Guidelines® Insights: Hodgkin Lymphoma, Version 2.2022

NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer.

scientific article published on May 2007

New Treatment Algorithms in Hodgkin Lymphoma: Too Much or Too Little?

scientific article published on 01 May 2018

Nodular lymphocyte predominant Hodgkin lymphoma: executive summary of the American radium society appropriate use criteria

scientific article published on 04 December 2020

Non-Hodgkin lymphoma of the breast

scientific article published in July 2007

Non-Hodgkin's Lymphomas, version 3.2012

scientific article published on 01 December 2012

Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology

scientific article published on 01 March 2006

Non-Hodgkin's lymphomas

scientific article published on 01 April 2008

Non-Hodgkin's lymphomas

scientific article published on 01 May 2011

Non-Hodgkin's lymphomas, version 1.2013.

scientific article

Non-Hodgkin's lymphomas, version 2.2014

scientific article published on 01 June 2014

Non-Hodgkin's lymphomas, version 4.2014.

scientific article published on September 2014

Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing.

scientific article published on 17 April 2015

Novel Approaches in Waldenström Macroglobulinemia

scientific article published on 19 July 2018

Novel Salvage Regimens Lead to Better Response and Survival in Relapsed Refractory Classic Hodgkin Lymphoma after Autologous Stem Cell Transplant

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

scientific article published on 20 March 2014

Odronextamab, a human CD20×CD3 bispecific antibody in patients with CD20-positive B-cell malignancies (ELM-1): results from the relapsed or refractory non-Hodgkin lymphoma cohort in a single-arm, multicentre, phase 1 trial

Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study

scientific article published on 30 November 2016

Optimal Therapy of Advanced Hodgkin Lymphoma ⬇️

scientific article published on January 1, 2011

Outcomes Among Classical Hodgkin Lymphoma Patients After an Interim PET Scan: A Real-World Experience

Outcomes for Relapsed and Refractory Peripheral T-Cell Lymphoma Patients after Front-Line Therapy from the COMPLETE Registry

scientific article published on 17 July 2019

Outcomes in adolescents and young adults with Hodgkin lymphoma treated on US cooperative group protocols: An adult intergroup (E2496) and Children's Oncology Group (COG AHOD0031) comparative analysis.

scientific article

Outcomes of patients with limited-stage aggressive large B-cell lymphoma with high-risk cytogenetics

scientific article published on 01 January 2020

Overall Survival with Brentuximab Vedotin in Stage III or IV Hodgkin’s Lymphoma

Oxidation of hemoglobin F is associated with the aging process of neonatal red blood cells

scientific article published in August 1992

Oxidative red blood cell membrane injury in the pathophysiology of severe mouse beta-thalassemia ⬇️

scientific article published on February 15, 1992

PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome

scientific article

Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP.

scientific article published on 29 April 2008

Partial response or better at six months is prognostic of superior progression-free survival in Waldenström macroglobulinaemia patients treated with ibrutinib

scientific article published on 18 November 2020

Pathophysiological significance and therapeutic targeting of germinal center kinase in diffuse large B-cell lymphoma

scientific article published on 05 May 2016

Pembrolizumab and Chemotherapy in Newly-Diagnosed, Early Unfavorable or Advanced Stage Classic Hodgkin Lymphoma: The Phase 2 Keynote-C11 Study

Pembrolizumab followed by AVD in untreated early unfavorable and advanced stage classical Hodgkin lymphoma

scientific article published on 29 September 2020

Peripheral T cell lymphoma, not otherwise specified (PTCL-NOS). A new prognostic model developed by the International T cell Project Network

scientific article published on 19 April 2018

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the BCL2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory CD20+ lymphoid malignancies

scientific article

Phase 2 study of VcR-CVAD with maintenance rituximab for untreated mantle cell lymphoma: an Eastern Cooperative Oncology Group study (E1405).

scientific article published on 23 January 2014

Phase I Study of the Anti-CD22 Antibody-Drug Conjugate Pinatuzumab Vedotin with/without Rituximab in Patients with Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

scientific article published on 6 September 2016

Phase I and pharmacokinetic study of BMS-188797, a new taxane analog, administered on a weekly schedule in patients with advanced malignancies

scientific article published on November 2003

Phase I study of the humanized anti-CD40 monoclonal antibody dacetuzumab in refractory or recurrent non-Hodgkin's lymphoma

scientific article

Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies

scientific article

Phase II Investigator-Initiated Study of Brentuximab Vedotin in Mycosis Fungoides and Sézary Syndrome With Variable CD30 Expression Level: A Multi-Institution Collaborative Project

scientific article published on 20 July 2015

Phase II study of gefitinib, fluorouracil, leucovorin, and oxaliplatin therapy in previously treated patients with metastatic colorectal cancer

scientific article published in August 2005

Phase II study of rituximab given in conjunction with standard chemotherapy in primary central nervous system lymphoma (PCNSL): a trial of the ECOG-ACRIN cancer research group (E1F05).

scientific article published on 6 November 2017

Phase II study of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone immunochemotherapy followed by yttrium-90-ibritumomab tiuxetan in untreated mantle-cell lymphoma: Eastern Cooperative Oncology Group Study E1499

scientific article published on 30 July 2012

Phase Ib study of combinations of avadomide (CC‐122), CC‐223, CC‐292, and rituximab in patients with relapsed/refractory diffuse large B‐cell lymphoma

Plasma Epstein-Barr virus DNA predicts outcome in advanced Hodgkin lymphoma: correlative analysis from a large North American cooperative group trial.

scientific article published on 5 February 2013

Polatuzumab Vedotin Combined with R-ICE (PolaR-ICE) As Second-Line Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

scientific article published on 29 March 2019

Population pharmacokinetic model of ibrutinib, a Bruton tyrosine kinase inhibitor, in patients with B cell malignancies

scientific article published on 8 November 2014

Postibrutinib outcomes in patients with mantle cell lymphoma

scientific article

Prediction of survival in diffuse large B-cell lymphoma based on the expression of 2 genes reflecting tumor and microenvironment

scientific article

Primary Cutaneous Lymphomas

Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium

scientific article published on 09 September 2019

Prognostic factors and patterns of failure in advanced stage Hodgkin lymphoma treated with combined modality therapy

scientific article published on 06 July 2018

Prognostic factors in primary cutaneous anaplastic large cell lymphoma: characterization of clinical subset with worse outcome

scientific article published in June 2009

Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium.

scientific article published on 14 April 2017

Randomized Phase III Trial Comparing ABVD Plus Radiotherapy With the Stanford V Regimen in Patients With Stages I or II Locally Extensive, Bulky Mediastinal Hodgkin Lymphoma: A Subset Analysis of the North American Intergroup E2496 Trial

scientific article published on 20 April 2015

Randomized phase III trial of ABVD versus Stanford V with or without radiation therapy in locally extensive and advanced-stage Hodgkin lymphoma: an intergroup study coordinated by the Eastern Cooperative Oncology Group (E2496)

scientific article

Refinement of the Lugano Classification lymphoma response criteria in the era of immunomodulatory therapy.

scientific article published on 29 August 2016

Reply to J. Wang et al

scientific article published on 12 February 2019

Response to Brentuximab Vedotin by CD30 Expression in Non-Hodgkin Lymphoma

Response-adapted therapy for aggressive non-Hodgkin's lymphomas based on early [18F] FDG-PET scanning: ECOG-ACRIN Cancer Research Group study (E3404)

scientific article

Retreatment with brentuximab vedotin in patients with CD30-positive hematologic malignancies.

scientific article published on 19 March 2014

Risk of therapy-related secondary leukemia in Hodgkin lymphoma: the Stanford University experience over three generations of clinical trials

scientific article published on 7 January 2013

Risk stratification in extranodal natural killer/T-cell lymphoma

scientific article published on September 2010

Risk-Adapted Treatment of Advanced Hodgkin Lymphoma With PET-CT.

scientific article published on January 2016

Risk-adapted therapy for advanced-stage Hodgkin lymphoma

scientific article published on 01 November 2018

Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2

Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study.

scientific article published on 27 April 2015

Safety and efficacy of brentuximab vedotin for Hodgkin lymphoma recurring after allogeneic stem cell transplantation

scientific article

Sequential Pembrolizumab and AVD is Highly Effective at any PD-L1 Expression Level in Untreated Hodgkin Lymphoma

Single cell profiling of circulating tumor cells: transcriptional heterogeneity and diversity from breast cancer cell lines

scientific article

Speeding up PET/MR for cancer staging of children and young adults

scientific article published on 5 April 2016

Splenic diffuse large B-cell lymphoma in a patient with type 1 Gaucher disease: Diagnostic and therapeutic challenges

scientific article published on 26 August 2006

Stage I and II follicular non-Hodgkin's lymphoma: long-term follow-up of no initial therapy

scientific article published on 15 March 2004

Stage I-II Nodular Lymphocyte-Predominant Hodgkin Lymphoma: a Multi-institutional Experience of Adult Patients by ILROG

scientific article published on 25 March 2020

Stage I-IIA non-bulky Hodgkin's lymphoma. Is further distinction based on prognostic factors useful? The Stanford experience

scientific article

Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography

scientific article published in May 2006

Subsequent primary malignancies after diffuse large B-cell lymphoma in the modern treatment era.

scientific article published on 25 May 2017

Sézary syndrome: immunopathogenesis, literature review of therapeutic options, and recommendations for therapy by the United States Cutaneous Lymphoma Consortium (USCLC).

scientific article published on 09 December 2010

T follicular helper phenotype predicts response to histone deacetylase inhibitors in relapsed/refractory peripheral T-cell lymphoma

scientific article published on 01 October 2020

Targeted Mutational Profiling Reveals Clonal Relationships in Metachronous Occurrence of Classic Hodgkin and Mediastinal Large B-Cell Lymphomas

Targeted therapy in relapsed classical hodgkin lymphoma

scientific article

Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma.

scientific article published on 20 July 2015

Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma

scientific article

Targeting CD40 in Waldenström's macroglobulinemia

scientific article

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.

scientific article published on 15 April 2016

Template for Reporting Results of Biomarker Testing of Specimens From Patients With Diffuse Large B-Cell Lymphoma, Not Otherwise Specified.

scientific article

The 2016 revision of the World Health Organization classification of lymphoid neoplasms

scientific article published on 15 March 2016

The ECHELON-2 Trial: 5-year results of a randomized, phase III study of brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma

The Echelon-2 Trial: 5-Year Exploratory Subgroup Analyses of a Randomized, Double-Blind, Phase 3 Study of Brentuximab Vedotin and CHP (A+CHP) Vs CHOP in Frontline Treatment of Pts with CD30-Positive Peripheral T-Cell Lymphoma

The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

The Role of Radiation Therapy in Patients With Relapsed or Refractory Hodgkin Lymphoma: Guidelines From the International Lymphoma Radiation Oncology Group

scientific article published on 9 January 2018

The combination of ibrutinib and rituximab demonstrates activity in first-line follicular lymphoma

scientific article published on 16 March 2020

The efficacy and tolerability of adriamycin, bleomycin, vinblastine, dacarbazine and Stanford V in older Hodgkin lymphoma patients: a comprehensive analysis from the North American intergroup trial E2496

scientific article published on 29 January 2013

The emerging role for rituximab in the treatment of nodular lymphocyte predominant Hodgkin lymphoma

scientific article published on September 2009

The landscape of new drugs in lymphoma

scientific article published on 29 December 2016

The outcome of peripheral T-cell lymphoma patients failing first line therapy: a report from the prospective, international T-Cell project.

scientific article published on 29 March 2018

The role of autologous stem cell transplantation in patients with nodal peripheral T-cell lymphomas in first complete remission: Report from COMPLETE, a prospective, multicenter cohort study

scientific article published on 29 January 2019

Three-year outcomes with brentuximab vedotin plus bendamustine as first salvage therapy in relapsed or refractory Hodgkin lymphoma

scientific article published on 12 February 2020

Time Since Last Anti-CD20 Treatment Is a Major Determinant of Sars-Cov-2 Vaccine Response in a Large Cohort of Patients with B-Cell Lymphoma

Treatment of angioimmunoblastic T-cell lymphoma with cyclosporine

scientific article published on 01 June 1997

Treatment of mantle cell lymphoma: current approach and future directions

scientific article

Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensus

scientific article

Treatment recommendations from the Eighth International Workshop on Waldenström's Macroglobulinemia

scientific article published on 18 July 2016

Trial in Progress: First Report of the Phase 1/2 Study of the Safety and Efficacy of CPO107, a Bispecific Agent Targeting CD20/CD47 in CD20 Expressing Non-Hodgkin Lymphoma (NHL)

Tumor-associated macrophages predict inferior outcomes in classic Hodgkin lymphoma: a correlative study from the E2496 Intergroup trial

scientific article

Updates in Treatment Strategies for Hodgkin Lymphoma

scientific article published on 01 November 2019

Utility of Routine Surveillance Laboratory Testing in Detecting Relapse in Patients With Classic Hodgkin Lymphoma in First Remission: Results From a Large Single-Institution Study

scientific article published on 05 May 2020

Value of surveillance studies for patients with stage I to II diffuse large B-cell lymphoma in the rituximab era.

scientific article published in May 2015

Viral cfDNA Profiling Reveals Distinct EBV Subtypes and Stratifies Risk in Hodgkin Lymphomas

Voreloxin, a first-in-class anticancer quinolone derivative, in relapsed/refractory solid tumors: a report on two dosing schedules

scientific article

XVIII. Management of nodular lymphocyte predominant Hodgkin lymphoma

scientific article published on June 2015

Paulina is supported by:

About Paulina

Help